ABSTRACT
Introduction
Fungal biofilm-associated infections have emerged as an important health problem (1) . Biofilm yeast cells exhibit increased antifungal resistance, besides they are also protected from the immune system by the matrix, and may persist on the biomaterial surface and cause recalcitrant infections (2) . The limited effectiveness of current therapeutic strategies to eradicate fungal biofilm leads, in many cases, to device removal in order to cure the infection. Candida species are the most relevant fungal pathogens associated with device-related infections, since they are able to colonize and form biofilms on many surfaces used in current medical practice, such as polytetrafluoroethylene (PTFE) and titanium (3) . PTFE, commercially know as Teflon®, is commonly used in the manufacture of vascular devices and titanium is one of the metallic biomaterials used for joint arthroplasties.
Although Candida albicans is the most commonly involved yeast, Candida tropicalis has also emerged as an important pathogen that is associated with immunocompromised patients (4-6), intensive care units and patients with neutropenia. Two classes of antifungal agents, polyenes and echinocandins, have proven to be effective against Candida species biofilms (7-9) and several authors have proposed these agents for the systemic and local treatment (i.e., lock therapy) of long-term catheter-related Candida spp. infections (10) .
Most of the studies related to antifungal activity against Candida biofilm have been performed by measuring the metabolic activity of biofilms formed on polystyrene 96-well microtiter plates by the XTT reduction assay (9, 11) . Other biofilm growth systems have been developed for testing microbial biofilms (i.e., Calgary Biofilm Device, Robbins device and the CDC Biofilm Reactor [CBR]). The CBR, which has been standardized by the American Society for Testing Materials (Method E2562-12) (12) , is an effective tool for studying the interaction between biomaterial surfaces and microbial biofilms and also the activity of antimicrobial agents against mature biofilms (13, 14) .
The purpose of the present study was 1) to determine the time growth curves of C. tropicalis biofilms on 2 biomaterials with different physicochemical properties, such as PTFE (hydrophobic) and titanium (hydrophilic), using the CBR as an in vitro model; 2) to determine the susceptibility of planktonic and biofilm cells of C. tropicalis to amphotericin B (AMB) and anidulafungin (ANF); and 3) to analyze the time-kill assays of AMB plus ANF against C. tropicalis biofilms formed on PTFE and titanium in the CBR.
Materials and methods

The CDC biofilm reactor and biomaterials
BioSurface Technologies Corporation provided the CBR (model CBR 90-1) and the biomaterials. The CBR was equipped with 8 rods, each housing 3 removable disks of PTFE (Model RD 128-PTFE) or commercially pure titanium disks (Model RD128-Ti). Although we used commercially pure titanium, the surface of this biomaterial is oxidized in contact with oxygen and then biofilm grew on the titanium oxide. Each disk was 12.7 mm in diameter and 4 mm in thickness.
Antifungal drugs
AMB (Sigma-Aldrich) and ANF (Pfizer Pharmaceuticals Group) were dissolved in DMSO. The maximum DMSO concentration in the CBR was always ≤0.5%. Antifungal concentrations assayed were: AMB 40 mg/L and ANF 8 mg/L, concentrations that could be used for lock therapy in central venous catheters (15) .
Isolates, biofilm formation, susceptibility and hydrophobicity test
A total of 3 isolates of C. tropicalis, identified by their biochemical properties (YST ID card, Vitek 2; bioMérieux) were assayed, 2 of them recovered from catheters of patients with bloodstream infection (B11 and B12) and the reference strain C. tropicalis ATCC® 750. Biofilm-forming capacity of each strain was determined in triplicate by using the crystal violet staining as described by Stepanović et al (16) . Cut-off was defined as 3 times the standard deviations above the mean OD 550 of the wells without inoculum (only culture media). Strains were classified as high (4 × ODc≤OD 550 ), moderate (2 × ODc≤OD 550 ≤4 × ODc), weak (ODc≤OD 550 ≤2 × ODc) or nonbiofilm former (OD 550 ≤ODc) (16) . Susceptibility of planktonic cells to AMB and ANF was determined according to the CLSI broth microdilution method (M27-A3 document) (17) . ANF and AMB MICs were defined as the lowest drug concentration that caused a reduction of growth ≥50% and 100%, respectively, compared with the control (without antifungal agents). Biofilm MICs (BMIC) were determined by the XTT reduction assay according to the protocol described by Pierce et al (18, 19) . Antifungal agents were added to preformed 24-hour biofilms and incubated for 48 hours at 37°C. BMIC was defined as the lowest drug concentration of antifungal able to reduce biofilm metabolic activity by ≥50% (BMIC 50 ) or by ≥90% (BMIC 90 ). Cell surface hydrophobicity (CSH) was determined using the previously described water-cyclohexane biphasic assay, , which takes into account the number of cells removed from the aqueous phase (20) .
Biofilm formation and time-kill assays in the CBR
Prior to analysis, each isolate was subcultured twice on Sabouraud dextrose agar plates to ensure viability. The inoculum was prepared by suspending 1 to 3 colonies in phosphate buffered saline pH 7.3 (PBS) from a 24-hour culture and adjusting cell density to 2 McFarland standard providing 10 8 cfu/mL. Three CBRs, equipped with PTFE and titanium disks, were filled with 400 mL of Yeast Nitrogen Base medium (Difco Laboratories) supplemented with 100 mM glucose (YNBG) and inoculated with 1 mL of the inoculum suspension (final inoculum size ranged from 8 × 10 4 to 2.7 × 10 5 cfu/mL). The CBRs were then placed on stir plates set at 250 rpm. The temperature inside each CBR was maintained uniformly at 30°C ± 1 °C during all the experiment.
After 24 hours of incubation, 3 PTFE and 3 titanium disks were aseptically removed from each CBR and the number of viable cells on their surfaces were quantified after a vortexing -sonication procedure. After that, AMB (40 mg/L), ANF (8 mg/L) and AMB + AND (40 + 8 mg/L) were added to their respective CBR unit (time 0).
The number of viable biofilm cells on the PTFE and titanium disks was determined at 24, 48 and 72 hours after adding the antifungal agents. An additional CBR without antifungal agents and with 0.5% of DMSO was used as a control. At each time point, 3 disks were removed and rinsed with 14 mL of PBS to remove planktonic and placed in a tube containing 1 mL YNBG. Each tube, with the disk inside, was vortexed for 1 minute at 2,500 rpm, sonicated (Model Ultrasons-H; J.P Selecta) for 5 minutes at 50 kHz and vortexed again for 1 minute at 2,500 rpm to disaggregate cells attached to the disk surfaces. Afterwards, 0.1 mL of the fluid obtained was diluted (1:10, 1:100, 1:1,000 and 1:10,000) in saline solution and 0.1 mL of each dilution was plated on Brain Heart Infusion Agar (Becton Dickinson). The plates were incubated for 24 hours at 37°C. The results, expressed as cfu/mL, were transformed into Log 10 cfu/cm 2 . In order to minimize bias, both biomaterials were assayed in the same CBR. All experiments were performed in triplicate.
Data analysis
The AMB + ANF interaction, following the established criteria for synergism by time-kill curves (21, 22) 
Results
The selected strains formed biofilms on microtiter plates and were classified as high (B11), moderate (B12) and weak (ATCC® 750) (Tab. I). The number of viable cells attached at 24 hours was 4.85 Log 10 cfu/cm 2 on PTFE and 4.24 Log 10 cfu/cm 2 on titanium and no difference in cell count was observed with respect to 48, 72 and 96 hours of culture in the CBR. CSH was similar for both clinical isolates (B11 and B12), while the ATCC® strain was less hydrophobic. Planktonic cells of the 3 strains were susceptible to both antifungal agents (AMB MIC ≤0.5 mg/L and ANF MIC ≤0.03 mg/L). AMB BMIC 90 were >8 mg/L for the 2 clinical isolates and 4 mg/L for the ATCC® strain. ANF BMIC 50 were >16 mg/L (Tab. I). Figure 1 shows the reduction in biofilm viable cells formed on PTFE and titanium after exposure to AMB and ANF alone, and combined. Against the 3 isolates, AMB was the most active drug both on PTFE and titanium. On PTFE, AMB produced a reduction in viable cells ranging from 0.69 Log 10 cfu/ cm 2 to 3.56 Log 10 cfu/cm 2 depending on the strain (mean of the 3 strains: 2.23 ± 0.89 Log 10 ) and on titanium it was from 1.49 Log 10 cfu/cm 2 to 4.51 Log 10 cfu/cm 2 (mean: 2.91 ± 1.04 Log 10 ). At 24 hours, the difference in viable cells with respect to their control was significant in the 2 clinical isolates, but at 48 and 72 hours the difference was significant for the three strains (p<0.05).
ANF did not show activity against the clinical isolate B11. On PTFE the mean reduction was 0.78 ± 0. For the AMB + ANF combination, the reduction in viable cells was isolate-dependent. AMB lost activity when combined with ANF, mainly on the B11 isolate. The mean reduction in viable cells attached to PTFE was 1.8 ± 1.07 Log 10 cfu/cm 2 (range 0.22 to 3.54 Log 10 ) and on titanium 1.97 ± 0.49 Log 10 cfu/cm 2 (range 1.36 to 2.84 Log 10 ). The interaction was classified as indifferent on both biomaterials, but we observed a tendency to antagonism in the isolate with a high biofilm-forming capacity (B11).
In general, AMB was more active against biofilms formed on titanium than those formed on PTFE, and among isolates it was greater against B11. Similarly to PTFE, ANF was not active against B11 except at 72 hours, when the reduction in viable cells with respect to biofilm control was significant at the same time point. Moreover, the combination of AMB + ANF was less active than AMB alone. The difference in cfu/ cm 2 between antifungals alone and in combination was significant (p<0.05) both on PTFE and titanium.
Discussion
Our results show the influence of biomaterials and the biofilm-forming capacity of the isolates in the killing rates of AMB and ANF against C. tropicalis biofilms. In a previous study we found a tendency to antagonism between amphotericin B and anidulafungin against biofilms formed by a C. tropicalis clinical isolate with a high biofilm-forming capacity (23). Now we have extended the study to 2 C. tropicalis clinical isolates and the reference strain ATCC® 750, with different degrees of biofilm-forming capacity. Results show the poor response of C. tropicalis biofilm to ANF on both biomaterials, which remained colonized after 72 hours. This resistance of C. tropicalis biofilms to ANF has also been reported by other authors using different methodologies (8, 9, 24) . Timekill studies show that AMB is able to eliminate more than 99% of cells attached to both biomaterials, and even eradicate the biofilm formed on titanium by the 2 clinical isolates. On the contrary, AMB did not eradicate the biofilms formed on PTFE. Interestingly, these isolates have more biofilm-forming capacity (high and moderate) and hydrophobity (>73%) than the ATCC® reference strain (weak and CSH 21.7%). We cannot explain yet why AMB is more active against biofilms formed on titanium. More studies are needed to clarify this question, including those related to biofilm cytoarchitecture and matrix composition.
The activity of the combination of AMB + ANF against C. tropicalis biofilms at the concentration assayed is inferior to that of AMB alone on both surfaces. At the end of the experiment (72 hours), the interaction is indifferent on both PTFE and titanium ( Fig. 1) with a tendency to antagonism against the high biofilm-forming strain (B11), while against the weak biofilm former (ATCC® 750) the combination is only a little more active than the antifungals alone. However, this combination has been shown to be synergistic against other Candida species. Valentin et al obtained a synergistic interaction of AMB + ANF against biofilms of C. albicans and C. glabrata using the XTT reduction assay (25) . The results suggest that combination of ANF and AMB does not add benefits to the treatment of C. tropicalis biofilm-related infections (e.g., antimicrobial lock therapy), although further studies are required.
Most biofilm antifungal susceptibility studies that use the XTT reduction assay have been performed mainly against C. albicans and few data have been reported for other Candida species (8, 9, 26) . Although ANF has proven to be effective against C. albicans biofilms (8, 27) , our results show no effectiveness against C. tropicalis biofilms either by XTT reduction assay (BMIC 50 >16 mg/L) or CBR. These differences between species could be related to the cytoarchitecture and matrix composition reported (glucose in C. albicans and hexosamines in C. tropicalis) that could affect the antifungal penetration rate (28) (29) (30) .The different activity of antifungals on biomaterials could be associated with the difference in the hydrophobic properties of the PTFE surface and the hydrophilic characteristics of titanium. Several authors have studied the effect of the hydrophobicity of biomaterials on yeast biofilm growth rates (31) (32) (33) and our study suggests that it also affects killing rates.
One of the limitations of this study is the reduced number of isolates assayed, but they were specially selected for their different degrees of biofilm-forming capacity. Although only 1 concentration of each antifungal has been assayed, it was selected as a possible candidate for lock therapy in central venous catheters.
Conclusions
In conclusion, the present work reinforces the influence of biomaterials and biofilm-forming capacity in the killing rates of antifungal agents. Drug activity is dependent on strain and time, since AMB is more active than ANF on both biomaterials. The killing rates are higher on titanium surfaces than on PTFE. Results also underline the loss of AMB activity when combined with ANF, suggesting that no benefits are added to the treatment of C. tropicalis biofilm-related infections. There is a tendency to antagonism against the high biofilm-forming strain, while against the weak biofilm former the combination is a little more active than the antifungals alone. Further studies are required to extend this finding to other Candida species.
